Comparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients
Year: 2023
Type: article
Abstract: To describe the association between levels of homocitrulline (HCit) and the degree of albumin carbamylation in a cohort of hemodialyzed patients. Plasma total and protein-bound HCit concentrations in samples from hemodialyzed patients included in NICOREN trial were determined by LC-MS/MS at baseline and after 24 weeks of treatment with either sevelamer or nicotinamide. HCit concentrations at all timepoints and in both groups were positively and significantly correlated with the degree of albumin carbamylation. Plasma concentrations of total HCit, protein-bound HCit and carbamylated albumin did not decrease after 24 weeks of treatment with either sevelamer or nicotinamide. The present results demonstrate that plasma total and protein-bound HCit concentrations were closely associated with albumin carbamylation in hemodialyzed patients. Therefore, total and protein-bound HCit concentrations might be valuable biomarkers of the overall intensity of protein carbamylation in this context. Given the less complex and time-consuming analytical methods required, these markers should be favored in future clinical studies of carbamylation reaction.
Source: Amino Acids
Institutions: Centre Hospitalier Universitaire Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires, Université de Picardie Jules Verne, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Reims, Matrice Extracellulaire et Dynamique Cellulaire MEDyC, Université de Reims Champagne-Ardenne, Inserm, Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation, Université de Limoges, Hôpital Ambroise-Paré, Université de Versailles Saint-Quentin-en-Yvelines, Assistance Publique – Hôpitaux de Paris, Centre de recherche en Epidémiologie et Santé des Populations
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,590
Funders: Amgen, Eli Lilly and Company, Astellas Pharma
OpenAlex ID: W4385488358
